GSK pledges further trial transparency
pharmafile | March 26, 2009 | News story | Research and Development, Sales and Marketing |Â Â GSKÂ
GlaxoSmithKline is to make its clinical trials more transparent through a series of moves it believes will facilitate clinical research.
The company will expand publication of research into its medicines on its Clinical Study Register, including all analyses of multiple trials and observational studies that use patient data from real world settings.
The commitment extends to data from research programmes that have been abandoned and GSK will also submit clinical study results as manuscripts in peer-reviewed journals "wherever possible".
In addition it will give some interpretation of results even for studies that are not published and the names of investigators participating in newly-initiated GSK-sponsored trials will be included in the summary information posted to the Clinical Study Register.
From 2010, the company will also make public the names of US doctors and institutions which GSK has paid to conduct trials and details of payments for other types of research will also be made available.
The company has already pledged that it would detail speaking and consulting fees paid to US healthcare professionals and will now extend that to European doctors too.
Lower prices for poorer nations
Publishing its 2008 corporate social responsibility (CSR) report, GSK chief executive Andrew Witty said the company would also lower prices of some brands in poorer nations.
The cost of its patented medicines will be no higher than 25% of the developed world price, as long as this covers cost of goods, but Witty insisted the commitments were more than just headline-grabbing.
"We recognise that GSK has unique and privileged capabilities," he said. "As we move forward, we will continue to look for new ways and new partnerships to improve global public health and research."
Affordable patented medicines
The report builds on February's remarks by Witty, when he said GSK was going to make good its commitment to ensure patented medicines were more affordable.
As a result, from April GSK will drop its prices for 110 products and formulations by an average of 45% in the developing world.
The company is to look at what it calls a "more flexible approach" to intellectual property rights in a bid to stimulate research into medicines for neglected tropical diseases.
GSK will also put more than 500 granted patents and 300 pending applications into a 'patent pool' to help others to develop potential treatments.
It will also give details of the means by which third parties can request access to other information about its medicines.
The CSR report also showed that GSK's donations and support of charities increased by 13% last year to £124 million.
This includes £68m of product donations, £37m of cash, £15m of management costs and £4m of in-kind donations.
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
